Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.75 |
| ▸ | KDR | P35968 | 16/20 | 0.75 |
| ▸ | MST1R | Q04912 | 3/20 | 0.75 |
| ▸ | AXL | P30530 | 2/20 | 0.75 |
| ▸ | FLT3 | P36888 | 2/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | FYN | P06241 | 1/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
| ▸ | HCK | P08631 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | BCR | P11274 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | ABL2 | P42684 | 1/20 | 0.75 |
| ▸ | FRK | P42685 | 1/20 | 0.75 |
| ▸ | SYK | P43405 | 1/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.75 |
| ▸ | MERTK | Q12866 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104760 | 0.94 | MET (0.78) | METKDRMST1RAXLFLT3 | |
| SCHEMBL13926830 | 0.94 | MET (0.75) | METKDRMST1RAXLFLT3 | |
| Glesatinib SCHEMBL29351360 | 0.86 | MET (1.00) | METKDRMST1RAXLFLT3 | |
| Glesatinib SCHEMBL106319 | 0.86 | MET (1.00) | METKDRMST1RAXLFLT3 | |
| SCHEMBL2670909 | 0.85 | MET (0.70) | METKDRMST1RAXLFLT3 | |
| SCHEMBL10202011 | 0.85 | AXL (0.78) | METKDRMST1RAXLFLT3 | |
| SCHEMBL104761 | 0.85 | MET (0.69) | METKDRMST1RAXLFLT3 | |
| SCHEMBL2670515 | 0.82 | MET (0.89) | METKDRMST1RAXLFLT3 | |
| SCHEMBL103919 | 0.82 | MET (0.61) | METKDRMST1RAXLFLT3 | |
| SCHEMBL2673548 | 0.81 | MET (0.91) | METKDRMST1RAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MET 3/4885KDR 11/4885MST1R 104/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MET 3/4885KDR 11/4885MST1R 104/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MET 3/4885KDR 11/4885MST1R 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.